Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population

Psychiatry and Clinical Neurosciences

Volumn 57, Issue 2, 2003, Pages 153-159

  Jun, Tae Youn ^a   Pae, Chi Un ^a   Kim, Kwang Soo ^a   Han, Hoon ^b   Serretti, Alessandro ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

IL 10 gene promoter polymorphism; Korean population; Schizophrenia

Indexed keywords

DNA; INTERLEUKIN 10;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; DNA FINGERPRINTING; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; SINGLE STRAND CONFORMATION POLYMORPHISM;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; KOREA; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS (GENETICS); RISK FACTORS; SCHIZOPHRENIA;

EID: 0242684483     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2003.01095.x     Document Type: Article

References (44)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM-IV), 4th edn. American Psychiatric Press, Washington DC, 1994.
2. Kronfol Z, Remick DG. Cytokines and the brain: Implications for clinical psychiatry. Am. J. Psychiatry 2000; 157:683-694.
3. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995; 29: 141-152.
4. Müller N, Reidel M, Ackenheil M, Schwartz MS. The role of immune function in schizophrenia: An overview. Eur. Arch. Psychiatry Clin. Neurosci. 1999; 249: IV62-IV68.
5. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr. Res. 1997; 26: 227-233.
6. Pollmacher T, Haack M, Schuld A, Kraus T, Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. J. Psychiatr. Res. 2000; 34: 369-382.
7. Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr. Res. 2001; 50: 169-175.
8. Marx CE, Jarskog LF, Lauder JM et al. Cytokine effects on cortical neuron MAP-2 immunoreactivity: Implications for schizophrenia. Biol. Psychiatry 2001; 50: 743-749.
9. Ganguli R, Rabin BS, Belle SH. Decreased interleukin-2 production in schizophrenic patients. Biol. Psychiatry 1989; 26: 427-430.
10. Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS. Altered interleukin-2 production in schizophrenia: Association between clinical state and autoantibody production. Psychiatry Res. 1992; 44: 113-123.
11. Ganguli R, Brar JS, Chengappa KR et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch. Gen. Psychiatry 1995; 52: 668-672.
12. Villemain F, Chatenoud L, Galinowski A et al. Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production. Am. J. Psychiatry 1989; 146: 609-616.
13. Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment. Psychiatry Res. 1997; 71: 11-17.
14. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 1997; 247: 228-233.
15. Lin A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr. Res. 1998; 32: 9-15.
16. Naudin J, Mege JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 1996; 20: 269-273.
17. Shintani F, Kanba S, Maruo N et al. Serum interleukin-6 in schizophrenic patients. Life Sci. 1991; 49: 661-664.
18. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog. Neuropsychopharmacol. Biol. Psychiatry 1988; 22: 947-957.
19. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Production of cytokines in acute schizophrenic psychosis. Biol. Psychiatry 1996; 40: 1294-1297.
20. Laurent C, Thibaut F, Ravassard P et al. Detection of two new polymorphic sites in the human interleukin-1 beta gene: Lack of association with schizophrenia in a French population. Psychiatr. Genet. 1997; 7: 103-105.
21. Tatsumi M, Sasaki T, Sakai T et al. Genes for interleukin-2 receptor beta chain, interleukin-1 beta, and schizophrenia: No evidence for the association or linkage. Am. J. Med. Genet. 1997; 74: 338-341.
22. Meisenzahl EM, Rujescu D, Kirner A et al. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am. J. Psychiatry 2001; 158: 1316-1319.
23. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. Association between xG308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol. Psychiatry 2001; 6: 79-82.
24. Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry 1999; 4: 179-181.
25. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998; 41: 1090-1095.
26. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 1997; 24: 1-8.
27. Jun TY, Pae CU, Chae JH, Bahk WM, Kim KS, Han H. IL-10 gene polymorphism at position -819 for major depression and schizophrenia in the Korean population. Psychiatry Clin. Neurosci. 2002; 56: 177-180.
28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated acid. Nucl. Acids Res. 1988; 16: 1215.
29. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Erlbaum, Hillsdale, NJ, 1988.
30. Schwarz MJ, Müller N, Riedel M, Ackenheil M. The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 2001; 56: 483-486.
31. Pickard C, Mann C. Sinnott P et al. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J. Neuroimmunol. 1999; 101: 207-210.
32. Bachis A, Colangelo AM, Vicini S et al. Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J. Neurosci. 2001; 21: 3104-3112.
33. Eskdale J, Keijsers V, Huizinga T, Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun. 1999; 1: 151-155.
34. Hovatta I, Varilo T, Suvisaari J et al. A genome-wide search for schizophrenia genes in and internal isolates of Finland suggesting multiple susceptibility loci. Am. J. Med. Genet. 1998; 81: 453-454.
35. Shaw SH, Kelly M. Smith AB et al. A genome-wide search for schizophrenia susceptibility genes. Am. J. Med. Genet. 1998; 81: 364-376.
36. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999; 42: 1101-1108.
37. Chiavetto LB, Boin F, Zanardini R et al. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol. Psychiatry 2002; 51: 480-484.
38. Yamazaki K, Tabeta K, Nakajima T et al. Interleukin-10 gene promoter polymorphism in Japanese patients with adult and early-onset periodontitis. J. Clin. Periodontol. 2001; 28: 828-832.
39. Helminen ME, Kilpinen S, Virta M, Hurme M. Susceptibility to primary Epstein-Barr virus infection is associated with interleukin-10 gene promoter polymorphism. J. Infect. Dis. 2001; 184: 777-780.
40. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J. Med. Virol. 2001; 65: 510-516.
41. Falk CT, Rubinstein P. Haplotype relative risks: An easy reliable way to construct a proper control sample for risk calculations. Ann. Hum. Genet. 1987; 51: 227-233.
42. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet. 1993; 52: 506-516.
43. Khoury MJ, Yang Q. The future of genetic studies of complex human diseases: An epidemiologic perspective. Epidemiology 1998; 9: 350-354.
44. Schulze TG, Muller DJ, Krauss H et al. Caught in the trio trap? Potential selection bias inherent to association studies using parent-offspring trios. Am. J. Med. Genet. 2001; 105: 351-353.